Cardiac syndrome X and endothelial dysfunction: new concepts in prognosis and treatment

Area of Science:

• Cardiology
• Vascular Biology
• Internal Medicine

Background:

• Cardiac Syndrome X (CSX), or angina without significant coronary artery stenosis, was considered to have a good prognosis.
• Emerging evidence links CSX with endothelial dysfunction to a higher risk of adverse cardiac events.
• Pathophysiology theories highlight microvascular ischemia due to a dysfunctional vascular endothelium.

Purpose of the Study:

• To enhance understanding of Cardiac Syndrome X (CSX).
• To provide updated information on diagnosis and risk stratification for CSX patients.
• To explore promising therapeutic strategies targeting endothelial function in CSX.

Main Methods:

• Review of current literature on Cardiac Syndrome X (CSX).
• Analysis of newer data regarding prognosis and risk factors in CSX.
• Evaluation of therapeutic interventions aimed at improving endothelial function.

Main Results:

• CSX patients with endothelial dysfunction face increased risks of future adverse cardiac events.
• Microvascular ischemia resulting from endothelial dysfunction is a key pathophysiological factor.
• Treatments like statins, ACE inhibitors, estrogen, and lifestyle changes show promise.

Conclusions:

• Cardiac Syndrome X (CSX) requires re-evaluation regarding prognosis, especially in patients with endothelial dysfunction.
• Targeting endothelial function is crucial for managing CSX.
• Improved diagnostic and therapeutic approaches are needed for CSX management.